DK0814792T3 - Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase - Google Patents

Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase

Info

Publication number
DK0814792T3
DK0814792T3 DK96909808T DK96909808T DK0814792T3 DK 0814792 T3 DK0814792 T3 DK 0814792T3 DK 96909808 T DK96909808 T DK 96909808T DK 96909808 T DK96909808 T DK 96909808T DK 0814792 T3 DK0814792 T3 DK 0814792T3
Authority
DK
Denmark
Prior art keywords
oxide synthase
mercapto
nitric oxide
inhibitors
inhibiting
Prior art date
Application number
DK96909808T
Other languages
English (en)
Inventor
Garry J Southan
Andrew L Salzman
Csaba Szabo
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/410,312 external-priority patent/US5674907A/en
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of DK0814792T3 publication Critical patent/DK0814792T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96909808T 1995-03-24 1996-03-22 Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase DK0814792T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/410,312 US5674907A (en) 1995-03-24 1995-03-24 Mercapto derivatives as inhibitors of nitric oxide synthase
US08/545,952 US5929063A (en) 1995-03-24 1995-10-20 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
PCT/US1996/003838 WO1996030007A1 (en) 1995-03-24 1996-03-22 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase

Publications (1)

Publication Number Publication Date
DK0814792T3 true DK0814792T3 (da) 2003-09-29

Family

ID=27020952

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909808T DK0814792T3 (da) 1995-03-24 1996-03-22 Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase

Country Status (17)

Country Link
US (2) US5929063A (da)
EP (1) EP0814792B1 (da)
JP (1) JPH11502847A (da)
CN (1) CN1275594C (da)
AT (1) ATE241347T1 (da)
AU (1) AU695307B2 (da)
BR (1) BR9607951A (da)
CA (1) CA2214601C (da)
CZ (1) CZ293497A3 (da)
DE (1) DE69628416T2 (da)
DK (1) DK0814792T3 (da)
HU (1) HUP9801698A3 (da)
MX (1) MX9707278A (da)
NZ (1) NZ305228A (da)
RU (1) RU2191575C2 (da)
TR (1) TR199701013T1 (da)
WO (1) WO1996030007A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9707953A (pt) * 1996-03-05 2000-10-24 Childrens Hosp Medical Center Derivados de mercapto como inibidores de ciclooxigenases
AU3128197A (en) * 1996-05-30 1998-01-05 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
JP2001507696A (ja) 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション グルタチオンの医薬製剤およびその投与方法
FR2782642B1 (fr) * 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
US6653350B1 (en) 1998-09-08 2003-11-25 G.D. Searle & Co. Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
EP1931328A4 (en) * 2005-08-16 2011-07-13 Discogen Llc METHOD FOR TREATING A GREENER SUBJECT WITH DEGENERATIVE DISCOPATHY USING AN INHIBITOR OF NITRIC OXIDE SYNTHASE
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
WO2008128189A1 (en) 2007-04-13 2008-10-23 The Penn State Research Foundation Anti-cancer compositions and methods
US8003633B1 (en) 2008-04-14 2011-08-23 The Penn State Research Foundation Anti-cancer compositions and methods
CN114057619B (zh) * 2020-07-31 2024-03-22 深圳福山生物科技有限公司 有机硒化合物及其治疗用途
CN115785573B (zh) * 2022-12-02 2024-05-17 福建奥翔体育塑胶科技股份有限公司 一种持久抗菌型epdm颗粒及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400319A (en) * 1972-04-20 1975-07-16 Smith Kline French Lab Pharmaceutical compositions
EP0547558B1 (en) * 1991-12-16 2000-04-19 Washington University Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
JPH08503940A (ja) * 1992-11-27 1996-04-30 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬

Also Published As

Publication number Publication date
MX9707278A (es) 1998-06-30
HUP9801698A3 (en) 2000-07-28
JPH11502847A (ja) 1999-03-09
BR9607951A (pt) 1999-06-01
TR199701013T1 (xx) 1998-02-21
AU695307B2 (en) 1998-08-13
US5985917A (en) 1999-11-16
CN1181700A (zh) 1998-05-13
AU5319196A (en) 1996-10-16
WO1996030007A1 (en) 1996-10-03
DE69628416D1 (de) 2003-07-03
RU2191575C2 (ru) 2002-10-27
HUP9801698A2 (hu) 1998-11-30
US5929063A (en) 1999-07-27
CN1275594C (zh) 2006-09-20
CZ293497A3 (cs) 1998-02-18
DE69628416T2 (de) 2004-05-06
ATE241347T1 (de) 2003-06-15
CA2214601C (en) 2001-09-25
NZ305228A (en) 1999-01-28
CA2214601A1 (en) 1996-10-03
EP0814792B1 (en) 2003-05-28
EP0814792A1 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
DK0814792T3 (da) Mercapto- og selenderivater som inhibitorer af nitritoxidsyntase
MX9800411A (es) Compuestos quimicos.
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
TR200100472T2 (tr) Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
BR9811099A (pt) Inibidores de urocinase
MXPA05006194A (es) Metodo para utilizar una composicion de bebida.
NO963860L (no) Isoprenyl-transferase-inhibitorer
WO2001052796A3 (en) Methods of using a beverage composition for treating dental erosion
TR200103099T2 (tr) Fosfodiesteraz IVinhibitörü 1-amino triazoloc 4,3-a!kinazolin-5-on ve/veya-5-tionlar
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
JO1696B1 (en) Acetamide derivatives
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
WO2000078296A3 (en) Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2002005792A3 (en) Use of matrix metalloprotease inhibitors for the treatment of cancer
AU1759901A (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
TR199801731T2 (xx) Siklooksijenaz önleyicileri olarak merkapto türevleri.
AR026606A1 (es) Un metodo para prevenir la diarrea
WO2003000198A3 (en) Selective neuronal nitric oxide synthase inhibitors
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
PT1276722E (pt) Inibidores de naftamidina-uroquinase
NO970350L (no) Forbindelser anvendelige som anti-formeringsmidler og GARFT-inhibitorer
DK0971714T3 (da) Metode til anvendelse af cyklooxygenase-2-inhibitorer til behandling og forebyggelse af demens
MY127741A (en) Wash-off vitamin e compositions
AU2002254061A1 (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
ECSP961710A (es) Nuevos derivados de la etanolamina